

ORAL ORDER: Having reviewed the letters (D.I. 204 , 205), and considering that the objection to an in-person deposition appears to be based principally on the general reluctance of Mylans counsel to fly across the country, but also noting that Mylans law firm has about 250 lawyers in the Bay Area, one of whom entered an appearance in this case, and that the deponent has raised no objection based on the pandemic, I do not think there is any good reason not to conduct the deposition in person in the Bay Area. Takedas request for an in-person deposition is granted. Ordered by Judge Richard G. Andrews on 11/12/2021. (nms) (Entered: 11/12/2021)

As of November 15, 2021, PACER did not contain a publicly available document associated with this docket entry. The text of the docket entry is shown above.

Takeda Pharmaceuticals USA, Inc. v. Mylan Pharmaceuticals Inc.
1-19-cv-02216 (DDE), 11/12/2021, docket entry 207